

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: HENOT <i>et al.</i>	Confirmation No.: To Be Assigned Art Unit: To Be Assigned
Appl. No.: To Be Assigned (U.S. National Phase of PCT/EP2004/006733; Int'l. Filing Date: June 22, 2004)	Examiner: To Be Assigned
Filed: Herewith	Atty. Docket: 2447.0030000/ELE/LMB
For: Epitope Composition for Sublingual, Buccal or Enteric Administration Prepared by Hydrolysis of Antigenic Structures with Chymotrypsin	

**Information Disclosure Statement
Filing Under 37 C.F.R. § 1.97(b)**

Mail Stop PCT

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

Sir:

Listed on accompanying Forms PTO/SB/08A and PTO/SB/08B are documents that may be considered material to the examination of this application, in compliance with the duty of disclosure requirements of 37 C.F.R. §§ 1.56, 1.97 and 1.98. Copies of documents **FP1** and **NPL1-NPL2** are submitted. However, in accordance with 37 C.F.R. § 1.98(a)(2), a copy of the U.S. patent, document **US1**, cited on the attached Form PTO/SB/08A is not submitted.

Where the publication date of a listed document does not provide a month of publication, the year of publication of the listed document is sufficiently earlier than the effective U.S. filing date and any foreign priority date so that the month of publication is not in issue. Applicants have listed publication dates on the attached IDS Forms based on information presently available to the undersigned. However, the listed publication

dates should not be construed as an admission that the information was actually published on the date indicated.

Applicants reserve the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist. The Examiner is specifically requested not to rely solely on the material submitted herewith.

This Information Disclosure Statement is being filed within three months of the date of entry of the national stage as set forth in 37 C.F.R. § 1.491 in an international application. No statement or fee is required.

It is respectfully requested that the Examiner initial and return a copy of the enclosed IDS Forms, and indicate in the official file wrapper of this patent application that the documents have been considered.

10/561 175

WFO Rec'd PCT/PTO 16 DEC 2005

- 3 -

HENOT *et al.*
Appl. No. To Be Assigned
(U.S. National Phase of PCT/EP2004/006733)

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

Lori M. Brandes

Lori M. Brandes
Agent for Applicants
Registration No. 57,772

Date: December 16, 2005

1100 New York Avenue, N.W.
Washington, D.C. 20005-3934
(202) 371-2600

472463_1.DOC

10/561 175

Equivalent of Form PTO/SB/08A (07-05)
Approved for use through 07/31/2006.

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Collection of Information unless it contains a valid GOMR or a valid
GOMR-A.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO		I.A. Filing Date PCT/PTO 16 DEC 2004	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>		Application Number	To Be Assigned (U.S. National Phase of PCT/EP2004/006733)
		I.A. Filing Date	June 22, 2004
		First Named Inventor	Frédéric HENOT
		Art Unit	To Be Assigned
		Examiner Name	To Be Assigned
Sheet	1	of	1
		Attorney Docket Number	2447.0030000/ELE/LMB

472465 1.DOC

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. *Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. *Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). *For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. *Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. *Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

10/561175

IAP9 Rec'd PCT/PTO 16 DEC 2004

PTO/SB/08B (07-05)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

Complete if Known
**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet

1

of

1

Application Number	<i>To Be Assigned</i> (U.S. National Phase of PCT/EP2004/006733)
Filing Date	June 22, 2004
First Named Inventor	Frédéric HENOT
Art Unit	<i>To Be Assigned</i>
Examiner Name	<i>To Be Assigned</i>

Attorney Docket Number

2447.003000/ELE/LMB

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume issue number(s), publisher, city and/or country where published	T ²
	NPL1	Asselin, J., et al., "Effects of <i>In Vitro</i> Proteolysis on the Allergenicity of Major Whey Proteins," <i>J. Food Sci.</i> 54:1037-1039, IFT Publications (1989)	
	NPL2	Tanabe, S., et al., "Inhibition of Basophil Histamine Release by a Haptenic Peptide Mixture Prepared by Chymotryptic Hydrolysis of Wheat Flour," <i>Biochem. Biophys. Res. Comm.</i> 223:492-495, Academic Press, Inc. (1996)	

472472_1.DOC

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.